Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

TipRanks

Fri, Dec 6, 2024, 4:46 AM 1 min read

JMP Securities raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $427 from $415 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.